~Delete 33277 - История изменений

Moderator: Moderator переименовал страницу Thinking About Rapid Programs For Qsymia Reviews в ~Delete 33277: Spam

2025-12-26T19:25:59Z

Moderator переименовал страницу Thinking About Rapid Programs For Qsymia Reviews в ~Delete 33277: Spam

Moderator: Spam cleanup

2025-12-26T19:25:56Z

Spam cleanup

Dugout28poland: Новая: About two years ago I wrote concerning the two most up-to-date weight reduction drugs rejected by the FDA. Among these drugs was Qnexa a mixture pill created up of two effectively establ...

2013-04-02T12:43:23Z

Новая: About two years ago I wrote concerning the two most up-to-date weight reduction drugs rejected by the FDA. Among these drugs was Qnexa a mixture pill created up of two effectively establ...

Новая страница

About two years ago I wrote concerning the two most up-to-date weight reduction drugs rejected by the FDA. Among these drugs was Qnexa a mixture pill created up of two effectively established medicines, phentermine and topiramate (Topamax). At that time the FDA felt there was not adequate facts concerning the prospective cardiac risks from the drug to allow its marketing and advertising inside the U.S. Now precisely the same drug, produced by exactly the same organization, Vivus, has not too long ago been approved by the FDA under a distinct name, Qsymia. Among the terms of approval is that the organization will conduct on-going surveillance research in the cardiovascular risk of applying this drug.

The FDA prescribing suggestions for Qsymia are surprisingly lenient, requiring only that an otherwise healthier patient have a BMI of 30 or additional. or for a person with underlying illnesses for instance diabetes, a BMI of 27 or much more. As an instance, at five foot five inches an individual using a BMI of 27 will weigh 165 lb and for the exact same height a BMI of 30 is 180 lb.

Qsymia is composed of two drugs with long-standing FDA approval. Topiramate was approved in 1996 for remedy of epilepsy and phentermine has been available on the market since 1959. Both drugs are identified to suppress appetite and are associated with weight loss. In Qsymia, a extended acting version of topiramate and phenteramine are combined in a ratio of 6:1. In a 1 year study carried out by Vivus, obese subjects taking the higher dose of Qsymia lost on average an impressive 9% of their weight.[http://www.youtube.com/watch?v=3ZW5hDfiTWA Qsymia]

In 2010, I predicted it would take 10 years for drugs like Qsymia to obtain acceptance by the FDA. Clearly I was incorrect by eight years but I wonder what occurred previously two years. The key concern expressed by the FDA in 2010 was prospective for cardiovascular complications of utilizing this drug combination. I've not been in a position to discover any substantial studies offering reassurance about this prospective complication. The FDA is requiring on-going surveillance studies to detect these troubles but how will that perform for all those who take the drug now and are at prospective risk?

I believe it truly is smart to become skeptical of drug corporation sponsored studies. Speak about conflict of interest! However the danger of those drugs is well-known in light with the lengthy history of use by both up until now. 1 particularly powerful warning from Vivus is that girls at risk of becoming pregnant have to not acquire this drug. Another situation of approval for Qsymia by the FDA should be to limit the pharmacies permitted to dispense the drug and for physicians to complete a simple instruction program before becoming permitted to prescribe it. I'm eager to see how this functions out. Painful recollections of the Fen-Phen debacle 15 years ago, creates a degree of anxiousness for many seasoned physicians when pondering of prescribing a new fat reduction drug. Given the restricted number of offered options for treating those with obesity who are at danger for complications of diabetes, hypertension, arthritis and so on. it is actually still a tempting new chance.

← Предыдущая		Версия 19:25, 26 декабря 2025
Строка 1:		Строка 1:
−	About two years ago I wrote concerning the two most up-to-date weight reduction drugs rejected by the FDA. Among these drugs was Qnexa a mixture pill created up of two effectively established medicines, phentermine and topiramate (Topamax). At that time the FDA felt there was not adequate facts concerning the prospective cardiac risks from the drug to allow its marketing and advertising inside the U.S. Now precisely the same drug, produced by exactly the same organization, Vivus, has not too long ago been approved by the FDA under a distinct name, Qsymia. Among the terms of approval is that the organization will conduct on-going surveillance research in the cardiovascular risk of applying this drug.	+	Content removed
−
−	The FDA prescribing suggestions for Qsymia are surprisingly lenient, requiring only that an otherwise healthier patient have a BMI of 30 or additional. or for a person with underlying illnesses for instance diabetes, a BMI of 27 or much more. As an instance, at five foot five inches an individual using a BMI of 27 will weigh 165 lb and for the exact same height a BMI of 30 is 180 lb.
−
−	Qsymia is composed of two drugs with long-standing FDA approval. Topiramate was approved in 1996 for remedy of epilepsy and phentermine has been available on the market since 1959. Both drugs are identified to suppress appetite and are associated with weight loss. In Qsymia, a extended acting version of topiramate and phenteramine are combined in a ratio of 6:1. In a 1 year study carried out by Vivus, obese subjects taking the higher dose of Qsymia lost on average an impressive 9% of their weight.[http://www.youtube.com/watch?v=3ZW5hDfiTWA Qsymia]
−
−	In 2010, I predicted it would take 10 years for drugs like Qsymia to obtain acceptance by the FDA. Clearly I was incorrect by eight years but I wonder what occurred previously two years. The key concern expressed by the FDA in 2010 was prospective for cardiovascular complications of utilizing this drug combination. I've not been in a position to discover any substantial studies offering reassurance about this prospective complication. The FDA is requiring on-going surveillance studies to detect these troubles but how will that perform for all those who take the drug now and are at prospective risk?
−
−	I believe it truly is smart to become skeptical of drug corporation sponsored studies. Speak about conflict of interest! However the danger of those drugs is well-known in light with the lengthy history of use by both up until now. 1 particularly powerful warning from Vivus is that girls at risk of becoming pregnant have to not acquire this drug. Another situation of approval for Qsymia by the FDA should be to limit the pharmacies permitted to dispense the drug and for physicians to complete a simple instruction program before becoming permitted to prescribe it. I'm eager to see how this functions out. Painful recollections of the Fen-Phen debacle 15 years ago, creates a degree of anxiousness for many seasoned physicians when pondering of prescribing a new fat reduction drug. Given the restricted number of offered options for treating those with obesity who are at danger for complications of diabetes, hypertension, arthritis and so on. it is actually still a tempting new chance.

← Предыдущая	Версия 19:25, 26 декабря 2025
(нет различий)